1.28
Pulmonx Corp Aktie (LUNG) Neueste Nachrichten
Pulmonx Corporation Q1 2026 Financial Report Highlights, Forward-Looking Statements, and Key Risk Factors - Minichart
Pulmonx (NASDAQ: LUNG) secures $40M Perceptive loan and ends Q1 with $61.6M cash - Stock Titan
Pulmonx Corp 1Q 2026: Revenue $20.59M, EPS ($0.33) — 10-Q Summary - TradingView
Pulmonx (NASDAQ:LUNG) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Pulmonx (LUNG) Q1 2026 Earnings Transcript - AOL.com
LUNG Maintained by D. Boral Capital -- Price Target Stays at $14 - GuruFocus
Pulmonx Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Pulmonx's (LUNG) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives - GuruFocus
Is Pulmonx (LUNG) 85.3% Undervalued After Q1 2026 Beats? EPS -$0 - GuruFocus
Pulmonx (LUNG) Projects 2026 Revenue Between $90M and $92M - GuruFocus
Pulmonx Q1 Earnings Call Highlights - MarketBeat
Pulmonx (LUNG) Reports Strong Q1 Revenue Growth - GuruFocus
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Pulmonx Q1 2026 reveals mixed results, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Pulmonx Q1 2026 reveals mixed results, stock dips - Investing.com Canada
Pulmonx Corporation (LUNG) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Pulmonx Corp (NASDAQ:LUNG) Q1 2026 Revenue Miss and Falling Sales Drag Down Sentiment - ChartMill
Pulmonx (NASDAQ:LUNG) Releases Quarterly Earnings Results, Meets Expectations - MarketBeat
Pulmonx Reports First Quarter 2026 Financial Results - The Manila Times
Pulmonx (NASDAQ: LUNG) Q1 revenue falls 9% but 2026 outlook reaffirmed - Stock Titan
No China sales cut Pulmonx revenue 9%, but 2026 forecast holds - Stock Titan
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference - The Manila Times
Pulmonx webcast set for May 12 Bank of America health conference - Stock Titan
LUNG (Pulmonx Corporation) rises 5.63% on narrower Q4 2025 losses and steady 8% year over year revenue growth.Management Guidance - UBND thành phố Hải Phòng
[ARS] Pulmonx Corp SEC Filing - Stock Titan
Executive pay and board votes at Pulmonx (NASDAQ: LUNG) 2026 meeting - Stock Titan
Pulmonx (LUNG) Projected to Post Earnings on Wednesday - MarketBeat
How The Pulmonx (LUNG) Investment Narrative Is Resetting Around A Lower Target And Execution Risk - Yahoo Finance
Pulmonx Corporation (NASDAQ:LUNG) Short Interest Update - MarketBeat
Pulmonx sets April 29 earnings release, 4:30 p.m. ET webcast - Stock Titan
LUNG Stock Price, Quote & Chart | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Pulmonx Corp stock (US74586W1018): Is its airway treatment edge strong enough to unlock new upside? - AD HOC NEWS
Pulmonx (NASDAQ:LUNG) Stock Price Up 2.3%Still a Buy? - MarketBeat
Pulmonx Insiders Forfeit On 14% Gains After Selling Stock - Sahm
How The Pulmonx (LUNG) Investment Story Is Shifting After Q4 And New Guidance - Yahoo Finance
Pulmonx (LUNG) Projects 2026 Financial Outlook with Revenue and Margin Targets - GuruFocus
Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips - Investing.com
Rate Hike: Is Pulmonx Corporation stock trending bullishWeekly Profit Summary & Safe Capital Growth Plans - baoquankhu1.vn
Vanguard discloses zero Pulmonx holdings after internal realignment (NASDAQ: LUNG) - Stock Titan
If You Invested $1,000 in Pulmonx Corp (LUNG) - Stock Titan
How The Pulmonx (LUNG) Narrative Is Resetting Around Execution Risks And Fair Value Assumptions - Yahoo Finance
LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonx Corp Stock (ISIN: US74586W1018) Trades at Multi-Year Lows Amid Growth Potential in Lung Ther - AD HOC NEWS
Growth Value: Should I set a stop loss on Pulmonx CorporationBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Pulmonx Corporation 2025 Annual Report: Innovative COPD Solutions, Zephyr Valve Clinical Data, and Global Market Strategy - Minichart
LUNG Technical Analysis & ETF Price Forecast - Intellectia AI
Pulmonx (NASDAQ: LUNG) expands emphysema device business but remains unprofitable - Stock Titan
Pulmonx 2025 10-K: Revenue $90.5M, EPS (Loss) $(1.33) - TradingView
Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens - Quiver Quantitative
Soleus group holds 2.67M Pulmonx shares (LUNG) — 6.5% stake disclosed - Stock Titan
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):